Skip to main content

Table 2 Meta-Analysis of the pooled association between KIR polymorphisms and SSc

From: Evaluation of the association between KIR polymorphisms and systemic sclerosis: a meta-analysis

KIR geneNo. of studiesSSc
Positive (%), Negative (%) / Total
Control
Positive (%), Negative (%) / Total
P-valuePooled OR
(95% CI)
Heterogeneity Test
Q, I2%; P-value
Publication Bias
(Begg’s Test, P-value; Egger’s test, P-value)
Effect Model
2DL15550 (96.3%), 21 (3.7%) / 571765 (96.1%), 31 (3.9%) / 7960.6601.14 (0.64–2.0)(3.17, 0.0%; P = 0.52)(Begg’s Test, 0.99; Egger’s test, 0.43)Fixed
2DL25283 (49.5%), 288 (51.5%) / 571444 (55.8%), 352 (44.2%) / 7960.8750.94 (0.42–2.07)(39.87, 89.97%; P < 0.001)(Begg’s Test, 0.99; Egger’s test, 0.86)Random
2DL35498 (87.2%), 73 (12.8%) / 571710 (89.2%), 86 (10.8%) / 7960.3060.84 (0.60–1.17)(4.02, 53%; P = 0.40)(Begg’s Test, 0.70; Egger’s test, 0.59)Fixed
2DL44467 (99.6%), 2 (0.4%) / 469696 (100%), 0 (0%) /6960.3350.42 (0.07–2.47)(0.2, 0.0%; P = 0.97)(Begg’s Test, 0.99; Egger’s test, 0.81)Fixed
2DL54180 (38.4%), 289 (61.6%) / 469273 (39%), 423 (61%) / 6960.4650.91 (0.71–1.17)(2.19, 0.0%; P = 0.53)(Begg’s Test, 0.39; Egger’s test, 0.09)Fixed
2DS15285 (49.9%), 286 (50.1%) / 571427 (53.6%), 369 (46.4%) / 7960.920.98 (0.60–1.58)(13.76, 70.9%; P = 0.008)(Begg’s Test, 0.99; Egger’s test, 0.73)Random
2DS25322 (56.4%), 249 (43.6%) /571445 (55.9%), 351 (44.1%) / 7960.9231.01 (0.81–1.26)(3.29, 0.0%; P = 0.51)(Begg’s Test, 0.29; Egger’s test, 0.17)Fixed
2DS35193 (24.3%), 378 (75.7%) / 571260 (32.7%), 536 (67.3%) / 7960.5821.07 (0.85–1.34)(7.25, 44.89%; P = 0.122)(Begg’s Test, 0.12; Egger’s test, 0.16)Fixed
2DS45321 (56.2%), 250 (43.8%) / 571395 (49.6%), 401 (50.4%) / 7960.8381.03 (0.75–1.45)(2.61, 0.0%; P = 0.62)(Begg’s Test, 0.85; Egger’s test, 0.19)Fixed
2DS54164 (35%), 305 (65%) /469258 (37.1%), 438 (62.9%) / 6960.4440.81 (0.47–1.39)(9.11, 67.10%; P = 0.02)(Begg’s Test, 0.99; Egger’s test, 0.73)Random
3DL15535 (93.7%), 38 (6.3%) / 571739 (92.8%), 57 (7.2%) / 7960.6831.09 (0.71–1.70)(3.78, 0.0%; P = 0.43)(Begg’s Test, 0.99; Egger’s test, 0.28)Fixed
3DL24467 (99.6%), 2 (0.4%) / 469692 (99.4%), 4 (0.6%) / 6960.9021.09 (0.27–4.40)(0.38, 0.0%; P = 0.94)(Begg’s Test, 0.90; Egger’s test, 0.53)Fixed
3DL34467 (98.9%), 5 (1.1%) / 472696 (99.6%), 3 (0.4%) /6990.5340.64 (0.155–2.63)(0.001, 0.0%; P = 0.99)(Begg’s Test, 0.99; Egger’s test, 0.60)Fixed
3DS15256 (44.8%), 315 (5.2%) / 571342 (43%), 454 (57%) / 7960.3771.10 (0.88–1.37)(2.68, 0.0%; P = 0.61)(Begg’s Test, 0.19; Egger’s test, 0.11)Fixed
2DP14460 (98.1%), 9 (1.9%) / 469672 (96.5%), 24 (3.5%) / 6960.1821.672 (0.79–3.56)(6.99, 57.13%; P = 0.07)(Begg’s Test, 0.73; Egger’s test, 0.56)Fixed
3DP13150 (42.4%), 204 (57.6%) / 354230 (39.6%), 351 (60.4%) / 5810.1521.28 (0.91–1.81)(0.94, 0.0%; P = 0.62)(Begg’s Test, 0.90; Egger’s test, 0.47)Fixed
  1. 1. Momot T, Koch S, Hunzelmann N, Krieg T, Ulbricht K, Schmidt RE, et al. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis and rheumatism. 2004;50 (5):1561–5
  2. 2. Salim PH, Jobim M, Bredemeier M, Chies JA, Brenol JC, Jobim LF, et al. Characteristics of NK cell activity in patients with systemic sclerosis. Revista brasileira de reumatologia. 2013;53 (1):66–74
  3. 3. Tozkir JD, Tozkir H, Gurkan H, Donmez S, Eker D, Pamuk GE, et al. The investigation of killer cell immunoglobulin-like receptor genotyping in patients with systemic lupus erytematosus and systemic sclerosis. Clinical rheumatology. 2016;35 (4):919–25
  4. 4. Mahmoudi M, Fallahian F, Sobhani S, Ghoroghi S, Jamshidi A, Poursani S, et al. Analysis of killer cell immunoglobulin-like receptors (KIRs) and their HLA ligand genes polymorphisms in Iranian patients with systemic sclerosis. Clinical rheumatology. 2017;36 (4):853–62
  5. 5. Machado-Sulbaran AC, Ramirez-Duenas MG, Navarro-Zarza JE, Munoz-Valle JF, Mendoza-Carrera F, Banos-Hernandez CJ, et al. KIR/HLA Gene Profile Implication in Systemic Sclerosis Patients from Mexico. Journal of immunology research. 2019;2019:6808061